RSS

Duchenne muscular dystrophy

This year will be big for Duchenne muscular dystrophy (DMD) as interest in treatments is on the rise and deal activity is increasing, reported data and analytics company, GlobalData. more

Analysis

Leaders from the pharmaceutical industry are set to join forces for the generation, alignment and sharing of disease-level data across an entire condition for health technology assessments (HTA). more

News

A new charity-industry initiative has been launched by Duchenne UK, a muscular dystrophy charity, aimed at pioneering a new approach to health technology assessment. more

News

Gene control company, Synpromics, and life sciences company, Solid Biosciences, have entered into a research partnership for the development of new treatment options for Duchenne muscular dystrophy (DMD). more

News

Swiss specialty pharmaceutical company, Santhera Pharmaceuticals, has received a negative opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) for its revised marketing authorisation application for Raxone in DMD more

News

Santhera Pharmaceuticals has announced that the MHRA has granted a positive scientific opinion through the Early Access to Medicines Scheme (EAMS) to Raxone (idebenone) for patients with respiratory function decline not taking glucocorticoids in DMD more

News